APhA
This article was originally published in The Tan Sheet
Executive Summary
Group recently adopted policy encouraging manufacturers and FDA "to transition non-sedating antihistamines from prescription to nonprescription status." Association likely will communicate position during May 11 NDAC meeting on petition to switch Claritin, Allegra and Zyrtec (1"The Tan Sheet" March 19, p. 3)
|
Group recently adopted policy encouraging manufacturers and FDA "to transition non-sedating antihistamines from prescription to nonprescription status." Association likely will communicate position during May 11 NDAC meeting on petition to switch Claritin, Allegra and Zyrtec (1 (Also see "Antihistamine OTC Switch Petition Slated For NDAC Debate May 11" - Pink Sheet, 19 Mar, 2001.)). |